Drugs / GC3111
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02813486 | Jun → Nov 2016 | diphtheria, pertussis, tetanus | Green Cross Corporation | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04238975 | Oct 2019 → Feb 2021 | diphtheria, pertussis, tetanus | Green Cross Corporation | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GC3111 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02813486 ↗ |
| Modality | Vaccine | “GC3111 vaccine” NCT02813486 ↗ |
| Route | Intramuscular | “0.5mL, Intramuscular” NCT02813486 ↗ |